Physician profile
Geraldine Lanman
NPI 1568417483
$6,303.96
in general payments reported to CMS, 2019-2025
47 companies · $912 in 2025
The $912 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,045 · 2020: $992 · 2021: $1,118 · 2022: $689 · 2023: $797 · 2024: $751 · 2025: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,366 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,365.55 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,162.93 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $611.72 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $482.00 | 2019-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $387.26 | 2019-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $375.75 | 2019-2025 | Wegovy, Saxenda, Rybelsus |
| Janssen Pharmaceuticals, INC | $298.86 | 2019-2022 | |
| Pfizer INC. | $270.35 | 2019-2025 | |
| Lilly USA, LLC | $252.30 | 2019-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $199.60 | 2019-2022 | |
| Astellas Pharma US INC | $193.02 | 2019-2025 | Veozah |
| Horizon Therapeutics Plc | $138.46 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.60 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $130.00 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $127.69 | 2019-2023 | Eliquis |
| Genzyme Corporation | $125.72 | 2024-2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $120.75 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Antares Pharma, INC. | $109.21 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Sumitomo Pharma America, INC. | $100.61 | 2024-2025 | Gemtesa |
| Amarin Pharma, INC. | $96.47 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $92.87 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $68.44 | 2023-2024 | Edarbyclor, Edarbyclor |
| Glaxosmithkline, LLC. | $66.74 | 2020-2023 | Arexvy, Shingrix |
| Vivus LLC | $65.52 | 2020-2024 | Qsymia |
| Acerus Pharmaceuticals Corporation | $56.49 | 2022 | |
| Eisai INC. | $55.36 | 2020-2021 | |
| Inspire Medical Systems, INC. | $48.43 | 2025 | Inspire |
| Genentech USA, INC. | $46.25 | 2020-2021 | |
| Philips North America LLC | $40.80 | 2021-2024 | (5044) Mcot |
| Allergan, INC. | $40.80 | 2019-2020 | |
| Almatica Pharma LLC | $38.79 | 2021 | |
| Arbor Pharmaceuticals, INC. | $35.83 | 2021-2022 | |
| Ascensia Diabetes Care US INC. | $34.70 | 2023 | |
| Idorsia Pharmaceuticals US INC | $32.82 | 2023 | Quviviq |
| Dexcom, INC. | $27.77 | 2023 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $27.71 | 2020 | |
| Cmp Pharma, INC. | $24.63 | 2023 | Norliqva, Tadliq, Carospir |
| Alexion Pharmaceuticals, INC. | $24.52 | 2023 | Strensiq |
| Sanofi-Aventis U.S. LLC | $22.71 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $21.19 | 2020 | |
| Phadia US INC. | $19.02 | 2023 | Immunocap |
| Cleerly, INC. | $17.79 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Lundbeck LLC | $14.32 | 2024 | Rexulti |
| Sanofi Pasteur INC. | $14.17 | 2024 | |
| Aytu Biopharma, INC. | $13.63 | 2020 | |
| Amneal Pharmaceuticals LLC | $13.58 | 2022 | |
| Seqirus USA INC | $13.15 | 2019 | |
| Celgene Corporation | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geraldine Lanman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.